ClinicalTrials.gov
public full text
Public Domain
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in onchocerciasis endemic areas with high levels of lymphatic filariasis co-endemicity receiving concomitant albendazole.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Ivermectin Versus Albendazole for Chronic Strongyloidiasis#1124645
- Contribution of P-glycoproteins to macrocyclic lactone tolerance in drug resistant nematodes#1146483
- Summary of Data Collected During Field Efficacy Trials of Florfenicol and Oxytetracycline Dihydrate in Controlling Mortality in Walleye ( Sander vitreus ) Because of Motile Aeromonad Infections#621658
- Twice Yearly Treatment for the Control of LF#993959
- Delineation of onchocerciasis operational transmission zones of Burkina Faso.#251381
Record · ID 916892
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive